NICE publish final draft guidance on lecanemab and donanemab
Further to The National Institute for Health and Care Excellence (NICE) publishing draft guidance for public consultation about Alzheimer’s treatments donanemab and lecanemab (that we reported on here: https://journalofdementiacare.co.uk/nice-publish-further-draft-guidance-on-lecanemab-and-donanemab), NICE has published final draft guidance that continues to not recommend donanemab and lecanemab for use on the NHS.
Explaining the decision, Helen Knight, NICE Director of Medicines Evaluation, says:
“The committee concluded the small benefits of donanemab and lecanemab shown in the clinical trials and the lack of long-term evidence of effectiveness, together with the substantial resources the NHS would need to commit to the treatments means if they were approved they could displace other essential treatments and services that deliver significant benefits to patients.”
Registered stakeholders have until 3 July to appeal against the final draft guidance.
You can find out more from NICE here: https://www.nice.org.uk/news/articles/the-benefits-of-alzheimers-treatments-donanemab-and-lecanemab-remain-too-small-to-justify-the-additional-costs-says-nice-in-final-draft-guidance